|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 95 No. 10 (May 15), 2000:
pp. 3183-3190
Interleukin-2 enhances the response of natural killer cells to
interleukin-12 through up-regulation of the interleukin-12 receptor
and STAT4
Kathy S. Wang,
David A. Frank, and
Jerome Ritz
From the Center for Hematologic Oncology, Department of Adult
Oncology, Dana-Farber Cancer Institute, and the Department of Medicine,
Brigham and Women's Hospital, Harvard Medical School, Boston, MA
02115.
Interleukin (IL)-12 plays a critical role in modulating the
activities of natural killer (NK) cells and T lymphocytes. In animal
models, IL-12 has potent antitumor effects that are likely mediated by
its ability to enhance the cytotoxic activity of NK cells and cytotoxic
T lymphocytes, and to induce the production of interferon (IFN)- by
NK and T cells. In addition to IL-12, NK cells are responsive to IL-2,
and may mediate some of the antitumor effects of IL-2. In this study,
we examine the interaction between IL-2 and the signaling events
induced by IL-12 in NK cells. We find that IL-2 not only up-regulates
the expression of IL-12R 1 and IL-12R2, it also plays an important
role in up-regulating and maintaining the expression of STAT4, a
critical STAT protein involved in IL-12 signaling in NK cells. In
contrast to the effects of IL-2 alone, expression of IL-12 receptors
and STAT4 are unaffected or decreased by IL-12 or the combination of
IL-2 and IL-12. Through expression of high levels of IL-12 receptors
and STAT4, IL-2-primed NK cells show enhanced functional responses to
IL-12 as measured by IFN- production and the killing of target
cells. NK cells from cancer patients who received low-dose IL-2
treatment also exhibited increased expression of IL-12 receptor chains,
suggesting that IL-2 may enhance the response to IL-12 in vivo. These
findings provide a molecular framework to understand the interaction
between IL-2 and IL-12 in NK cells, and suggest strategies for
improving the effectiveness of these cytokines in the immunotherapy of cancer.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Gong and T. R. Malek
Cytokine-Dependent Blimp-1 Expression in Activated T Cells Inhibits IL-2 Production
J. Immunol.,
January 1, 2007;
178(1):
242 - 252.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Zorn, E. A. Nelson, M. Mohseni, F. Porcheray, H. Kim, D. Litsa, R. Bellucci, E. Raderschall, C. Canning, R. J. Soiffer, et al.
IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo
Blood,
September 1, 2006;
108(5):
1571 - 1579.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Robertson, H.-C. Chang, D. Pelloso, and M. H. Kaplan
Impaired interferon-{gamma} production as a consequence of STAT4 deficiency after autologous hematopoietic stem cell transplantation for lymphoma
Blood,
August 1, 2005;
106(3):
963 - 970.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P B Thomas, T Albini, R K Giri, R F See, M Evans, and N A Rao
The effects of atorvastatin in experimental autoimmune uveitis
Br. J. Ophthalmol.,
March 1, 2005;
89(3):
275 - 279.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Athie-Morales, H. H. Smits, D. A. Cantrell, and C. M. U. Hilkens
Sustained IL-12 Signaling Is Required for Th1 Development
J. Immunol.,
January 1, 2004;
172(1):
61 - 69.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Feinmesser, B. Hardy, R. Sadov, A. Shwartz, P. Chretien, and M. Feinmesser
Report of a Clinical Trial in 12 Patients With Head and Neck Cancer Treated Intratumorally and Peritumorally With Multikine
Arch Otolaryngol Head Neck Surg,
August 1, 2003;
129(8):
874 - 881.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Bream, R. E. Curiel, C.-R. Yu, C. E. Egwuagu, M. J. Grusby, T. M. Aune, and H. A. Young
IL-4 synergistically enhances both IL-2- and IL-12-induced IFN-{gamma} expression in murine NK cells
Blood,
July 1, 2003;
102(1):
207 - 214.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Cleary, W. Tu, A. Enright, T. Giffon, R. Dewaal-Malefyt, K. Gutierrez, and D. B. Lewis
Impaired Accumulation and Function of Memory CD4 T Cells in Human IL-12 Receptor {beta}1 Deficiency
J. Immunol.,
January 1, 2003;
170(1):
597 - 603.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. ROOK, M. H. ZAKI, M. WYSOCKA, G. S. WOOD, M. DUVIC, L. C. SHOWE, F. FOSS, M. SHAPIRO, T. M. KUZEL, E. A. OLSEN, et al.
The Role for Interleukin-12 Therapy of Cutaneous T Cell Lymphoma
Ann. N.Y. Acad. Sci.,
September 1, 2001;
941(1):
177 - 184.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gorschluter, C. Ziske, A. Glasmacher, and I. G. H. Schmidt-Wolf
Current Clinical and Laboratory Strategies to Augment the Efficacy of Immunotherapy in Multiple Myeloma
Clin. Cancer Res.,
August 1, 2001;
7(8):
2195 - 2204.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. S. Wang, E. Zorn, and J. Ritz
Specific down-regulation of interleukin-12 signaling through induction of phospho-STAT4 protein degradation
Blood,
June 15, 2001;
97(12):
3860 - 3866.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Cooper, T. A. Fehniger, S. C. Turner, K. S. Chen, B. A. Ghaheri, T. Ghayur, W. E. Carson, and M. A. Caligiuri
Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset
Blood,
May 15, 2001;
97(10):
3146 - 3151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Virtaneva, F. A. Wright, S. M. Tanner, B. Yuan, W. J. Lemon, M. A. Caligiuri, C. D. Bloomfield, A. de la Chapelle, and R. Krahe
Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics
PNAS,
January 30, 2001;
98(3):
1124 - 1129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Chakir, A. A. Camilucci, L. G. Filion, and J. R. Webb
Differentiation of Murine NK Cells into Distinct Subsets Based on Variable Expression of the IL-12R{beta}2 Subunit
J. Immunol.,
November 1, 2000;
165(9):
4985 - 4993.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
